Market News AIOpen the app

Wedbush kept its Outperform rating for Tango Therapeutics but cut the price target from $45 to $40.

OpinionRead the original at moomoo.com
Neutral

Wedbush kept its Outperform rating but lowered its target from $45 to $40. Those mixed analyst views add no new information about Tango's business, so this report does not change its outlook.

TNGX · Tango Therapeutics, Inc.

AI read · Neutral

The AI's read

This is an analyst's opinion, not a new company result. Keeping the positive rating points one way, and lowering the target points the other. With no new information about Tango's treatments, trials, or finances, this report does not change the company's outlook.

Get alerts for TNGX

Follow Tango Therapeutics, Inc. (TNGX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TNGX
Free on the App Store and Google Play, or on the web.